Literature DB >> 23450068

Assessment of clinical benefit and quality of life in patients undergoing cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for management of peritoneal metastases.

Yue Zhu1, Nader Hanna, Cherif Boutros, H Richard Alexander.   

Abstract

Peritoneal metastasis is a significant clinical challenge; life expectancy following diagnosis is usually very short. Surgical cytoreduction with HIPEC is being used with increasing frequency in selected patients; most outcome data have shown that prolonged median survivals can be observed in selected patients. This review summarizes the published data related to outcome and quality of life after cytoreduction and HIPEC to provide insights into its use in patients with peritoneal carcinomatosis.

Entities:  

Keywords:  Cytoreduction surgery (CRS); Hyperthermic Intraperitoneal Chemotherapy (HIPEC); peritoneal metastases

Year:  2013        PMID： 23450068      PMCID： PMC3562622          DOI： 10.3978/j.issn.2078-6891.2012.053

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN： 2078-6891


  41 in total

Review 1.  Intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: current status and future directions.

Authors:  John H Stewart; Perry Shen; Edward A Levine
Journal:  Ann Surg Oncol       Date:  2005-08-18       Impact factor: 5.344

2.  Monitoring health outcomes following cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis.

Authors:  Richard P McQuellon; Suzanne C Danhauer; Gregory B Russell; Perry Shen; Joyce Fenstermaker; John H Stewart; Edward A Levine
Journal:  Ann Surg Oncol       Date:  2007-01-06       Impact factor: 5.344

3.  Toxicity and quality of life after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy.

Authors:  Todd M Tuttle; Yan Zhang; Edward Greeno; Amy Knutsen
Journal:  Ann Surg Oncol       Date:  2006-10-01       Impact factor: 5.344

Review 4.  A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma.

Authors:  T D Yan; L Welch; D Black; P H Sugarbaker
Journal:  Ann Oncol       Date:  2006-11-27       Impact factor: 32.976

5.  Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion.

Authors:  Marcello Deraco; Daisuke Nonaka; Dario Baratti; Paolo Casali; Juan Rosai; Rami Younan; Andreola Salvatore; Antonello D Cabras Ad; Shigeki Kusamura
Journal:  Ann Surg Oncol       Date:  2006-01-18       Impact factor: 5.344

6.  Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program.

Authors:  Coleman K Obasaju; Zhishen Ye; Antoinette J Wozniak; Chandra P Belani; Mary-Louise Keohan; Helen J Ross; Jonathan A Polikoff; David M Mintzer; Matthew J Monberg; Pasi A Jänne
Journal:  Lung Cancer       Date:  2006-11-07       Impact factor: 5.705

7.  [Peritoneal carcinomatosis. Surgical treatment, including hyperthermal intraperitoneal chemotherapy].

Authors:  G Glockzin; N Ghali; S A Lang; A Agha; H J Schlitt; P Piso
Journal:  Chirurg       Date:  2007-12       Impact factor: 0.955

8.  Survival and health outcomes after cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of appendiceal origin.

Authors:  Richard P McQuellon; Gregory B Russell; Perry Shen; John H Stewart; Weston Saunders; Edward A Levine
Journal:  Ann Surg Oncol       Date:  2007-11-20       Impact factor: 5.344

9.  Cytoreductive surgery and intraperitoneal chemo-hyperthermia for chemo-resistant and recurrent advanced epithelial ovarian cancer: prospective study of 81 patients.

Authors:  Eddy Cotte; Olivier Glehen; Faheez Mohamed; Franck Lamy; Claire Falandry; François Golfier; Francois Noel Gilly
Journal:  World J Surg       Date:  2007-09       Impact factor: 3.352

10.  Aggressive surgical management of peritoneal carcinomatosis with low mortality in a high-volume tertiary cancer center.

Authors:  Niraj J Gusani; Sung W Cho; Christos Colovos; Songwon Seo; Jan Franko; Scott D Richard; Robert P Edwards; Charles K Brown; Matthew P Holtzman; Herbert J Zeh; David L Bartlett
Journal:  Ann Surg Oncol       Date:  2007-12-12       Impact factor: 5.344
View more
  12 in total

1.  Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for resectable peritoneal metastases is feasible in elderly patients.

Authors:  Walid Ezzedine; Diane Mege; Mathilde Aubert; Julie Duclos; Rémy Le Huu Nho; Igor Sielezneff; Nicolas Pirro
Journal:  Updates Surg       Date:  2021-02-06

2.  Stimulated upregulation of HO-1 is associated with inadequate response of gastric and ovarian cancer cell lines to hyperthermia and cisplatin treatment.

Authors:  Vaidotas Cesna; Arturas Sukovas; Aldona Jasukaitiene; Giedre Silkuniene; Saulius Paskauskas; Zilvinas Dambrauskas; Antanas Gulbinas
Journal:  Oncol Lett       Date:  2019-06-18       Impact factor: 2.967

3.  Assessment of clinical benefit and quality of life in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for management of peritoneal carcinomatosis.

Authors:  Maheswari Senthil
Journal:  J Gastrointest Oncol       Date:  2013-03

Review 4.  Primary and metastatic peritoneal surface malignancies.

Authors:  Delia Cortés-Guiral; Martin Hübner; Mohammad Alyami; Aditi Bhatt; Wim Ceelen; Olivier Glehen; Florian Lordick; Robert Ramsay; Olivia Sgarbura; Kurt Van Der Speeten; Kiran K Turaga; Manish Chand
Journal:  Nat Rev Dis Primers       Date:  2021-12-16       Impact factor: 52.329

5.  Fear of Cancer Recurrence in peritoneal malignancy patients following treatment: a cross-sectional study.

Authors:  Rayan Taher; Norman John Carr; Nancy Vanderpuye; Sophia Stanford
Journal:  J Cancer Surviv       Date:  2022-07-28       Impact factor: 4.062

6.  PIPAC for the Treatment of Gynecologic and Gastrointestinal Peritoneal Metastases: Technical and Logistic Considerations of a Phase 1 Trial.

Authors:  Mustafa Raoof; Gautam Malhotra; Adrian Kohut; Michael O'Leary; Paul Frankel; Thuy Tran; Marwan Fakih; Joseph Chao; Dean Lim; Yanghee Woo; Isaac B Paz; Michael Lew; Mihaela C Cristea; Lorna Rodriguez-Rodriguez; Yuman Fong; Andrew Blakely; Richard Whelan; Marc A Reymond; Amit Merchea; Thanh H Dellinger
Journal:  Ann Surg Oncol       Date:  2021-08-13       Impact factor: 5.344

7.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in treatment of gastric cancer with peritoneal carcinomatosis.

Authors:  Lynne M Ellison; Yangao Man; Alexander Stojadinovic; Hongwu Xin; Itzhak Avital
Journal:  Chin J Cancer Res       Date:  2017-02       Impact factor: 5.087

8.  Perioperative management and postoperative outcome of patients undergoing cytoreduction surgery with hyperthermic intraperitoneal chemotherapy.

Authors:  Hamed Elgendy; Hanaa Nafady-Hego; Hanan M Abd Elmoneim; Talha Youssef; Abdulaziz Alzahrani
Journal:  Indian J Anaesth       Date:  2019-10-10

9.  Analysis of Bacterial and Fungal Infections after Cytoreduction Surgery and Hyperthermic Intraperitoneal Chemotherapy: An Observational Single-Centre Study.

Authors:  Talat A M Albukhari; Hanaa Nafady-Hego; Hamed Elgendy; Hanan M Abd Elmoneim; Asmaa Nafady; Abdulaziz M Alzahrani
Journal:  Int J Microbiol       Date:  2019-08-01

10.  Overall clinical and trichoscopic analysis performed in patients who underwent pressurized intraperitoneal aerosol chemotherapy (PIPAC) treatment for peritoneal carcinomatosis - initial trial preliminary report.

Authors:  Maciej Nowacki; Katarzyna Nowacka; Iwona Głowacka; Barbara Zegarska; Wojciech Zegarski
Journal:  Postepy Dermatol Alergol       Date:  2019-08-30       Impact factor: 1.837
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.